Latest Breaking News On - Great britain summary - Page 7 : comparemela.com

Galapagos NV: Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn s and Colitis Organization (ECCO) annual congress

Nine presentations demonstrate Galapagos' commitment to inflammation and the ulcerative colitis (UC) communityFour new analyses from Phase 3 SELECTION and SELECTION long term extension studies of Jyseleca

Region flamandeUnited kingdomNorthern irelandGreat britainAilsa hartStefan schreiberEdwardv loftus jrHaridarshan patelJames oliver lindsayAnna gibbinsKristina harrisJohan michael burischVan gijselSandra cauwenberghsSilvio daneseMarieke vermeersch

JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT

Mechelen, Belgium; 18 January 2022; 22.01 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the Medicines and Healthcare products.

United kingdomRegion flamandeNorthern irelandGreat britainVan gijselSandra cauwenberghsMarieke vermeerschAnna gibbinsIan bealesMichele mantoRuth wakemanNorwich university hospitalEuropean commissionGilead sciences incTherapeutic areas communicationsRegulatory agency

JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN

JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomRegion flamandeNorthern irelandGreat britainAnna gibbinsseniorIan bealesVan gijselseniorMichele mantoRuth wakemanNorwich university hospitalEuropean commissionGilead sciences incTherapeutic areas communicationsRegulatory agencyJapanese ministry of healthEuropean union

Investegate |Galapagos NV Announcements | Galapagos NV: JYSELECA® (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN

Investegate announcements from Galapagos NV, JYSELECA® (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN

United kingdomRegion flamandeNorthern irelandGreat britainVan gijselSandra cauwenberghsMarieke vermeerschAnna gibbinsIan bealesMichele mantoRuth wakemanNorwich university hospitalEuropean commissionGilead sciences incTherapeutic areas communicationsRegulatory agency

Galapagos NV: SELECTION study on filgotinib in ulcerative colitis published in The Lancet

Mechelen, Belgium; 4 June 2021; 07.01 CET; - Galapagos NV (Euronext & Nasdaq: GLPG) today announced that primary and secondary endpoint results from the phase 3 SELECTION induction

Region flamandeUnited kingdomGreat britainVan gijselElizabeth goodwinWalid abi saabCarmen vroonenAnna gibbinsGilead sciences incTherapeutic areas communicationsRegulatory agencyJapanese ministry of healthGlobal head of communications public affairsEuropean medicines agencyDevices agencyJapan pharmaceuticals